ALK News
@ALKNewsNow
Followers
46
Following
201
Media
0
Statuses
119
Curating & sharing the latest news & research on ALK+ lung cancer
United States
Joined July 2024
ALK Lung Cancer Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment .
aacrjournals.org
Alternative therapeutic strategies are required for TKI-resistant ALK+ LUAD. The authors show ALK+ LUAD has a myeloid cell–dominant immunosuppressive TME that can be reversed with inhibition of the...
0
0
0
RT @zjamesrogers: Huge thank you to @UpstageLungCanc for supporting our work understanding TKI resistance mechanisms in ALK lung cancer! @b….
0
3
0
RT @PrecisionClinMe: A review of 36 advanced lung adenocarcinoma cases with unusual ALK fusions reveals alectinib is a viable treatment opt….
academic.oup.com
Dear Editor,
0
2
0
RT @StephenVLiu: #ALK is a viable target even in squamous NSCLC, demonstrated by this case + review in @ClinicalLung. However, significant….
clinical-lung-cancer.com
MicroabstractThis study investigated the clinical benefit of ALK tyrosine kinase inhibitors (TKIs) in patients with ALK-rearranged lung squamous cell carcinoma (LUSC). A patient harboring a novel...
0
28
0
RT @APilling111: Delighted to share our team's latest work- A review of the unique metabolic landscape in ALK+ lung cancer:. ☑️Metabolic….
0
1
0
RT @StephenVLiu: Report @JTOonline shows weight gain with ALK TKIs greater than in trials. With lorlatinib, weight gain of at least 10% see….
jtocrr.org
Therapy-associated weight gain affects the quality of life and health of patients with ALK-positive NSCLC treated with tyrosine kinase inhibitors (TKIs). The severity and timing of real-world weight...
0
9
0
RT @lungoncdoc: Phase 3 ALKAZAR study evaluating Neladalkib (NVL-655) is actively enrolling patients with newly diagnosed ALK+ mNSCLC! #Haw….
0
10
0
RT @nuvalent: We’re looking forward to connecting with colleagues across the #OncologyCommunity at #ASCO25! Stop by our "Trial in Progress"….
0
3
0
RT @UKALK1: People with ALK+ are more likely to develop brain metastases than in other types of lung cancer. 1 in 4 already have brain met….
0
4
0
New report on pregnancy during ALK TKI treatment (lorlatinib) - an area lacking extensive research.
Brief report @JTOonline on pregnancy and healthy baby on lorlatinib for #ALK NSCLC. Lorlatinib held weeks 4-20, then resumed. At 20m post-partum, ongoing PR & no congenital abnormalities in baby despite PK showing placental transfer of lorlatinib.
0
0
2
Encouraging results from alectinib plus bevacizumab trial for treatment of ALK positive lung cancer.
nature.com
Nature Communications - Up to 25% of patients with ALK-rearranged non-small cell lung cancer (NSCLC) experience disease progression within the first year of targeted therapy. This work reports a...
0
0
0
RT @UpstageLungCanc: 🎙 NEW PODCAST EPISODE! Living with ALK+: Diagnosis, Treatment, & Hope. This episode features a powerful conversation b….
0
1
0
RT @OncologyTimes: Meet Sydney Barned, MD, internal medicine hospitalist, champion for care before the Senate, and Stage IV #ALK-positive #….
0
2
0
RT @MolOncology: MET and NF2 alterations confer primary and early resistance to first-line alectinib treatment in ALK-positive non-small-ce….
0
9
0
CCN1 knockdown could help reverse alectinib resistance.
Researchers show that suppressing NF-κB or CCN1 receptor could improve the sensitivity to alectinib, further suggesting that NF-κB and CCN1 might play a key role in overcoming reversible drug resistance. 💊. @cddpress |
0
0
1
RT @ShihchengGuo: A phosphoproteomic screen reveals that ALK signaling phosphorylates GUK1 at Y74, boosting GDP synthesis in ALK+ lung canc….
cell.com
Schneider et al. identify guanylate kinase 1 (GUK1), a GDP-synthesizing enzyme, as a target of oncogenic signaling in lung cancer. Phosphorylation of GUK1 augments nucleotide pools and is important...
0
2
0
RT @LuisLara_M: New in @JTOonline – Clinical and Research Reports. Can ctRNA improve liquid biopsy in ALK+ NSCLC?.Let’s talk numbers:. 🧬….
0
8
0
RT @BibliotecaHUCA: PubMed- Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic….
0
2
0